LT3921030T - 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai - Google Patents

1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai

Info

Publication number
LT3921030T
LT3921030T LTEPPCT/US2020/016499T LTUS2020016499T LT3921030T LT 3921030 T LT3921030 T LT 3921030T LT US2020016499 T LTUS2020016499 T LT US2020016499T LT 3921030 T LT3921030 T LT 3921030T
Authority
LT
Lithuania
Prior art keywords
kcnq
trifluoroethoxy
pyridin
agents
methyl
Prior art date
Application number
LTEPPCT/US2020/016499T
Other languages
English (en)
Lithuanian (lt)
Inventor
Helen Szekeres
Andrew Williams
Maria Whatton
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT3921030T publication Critical patent/LT3921030T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2020/016499T 2019-02-06 2020-02-04 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai LT3921030T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962801716P 2019-02-06 2019-02-06
US201962811038P 2019-02-27 2019-02-27
PCT/US2020/016499 WO2020163268A1 (en) 2019-02-06 2020-02-04 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators

Publications (1)

Publication Number Publication Date
LT3921030T true LT3921030T (lt) 2024-01-25

Family

ID=69743945

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2020/016499T LT3921030T (lt) 2019-02-06 2020-02-04 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai

Country Status (23)

Country Link
US (4) US11208383B2 (https=)
EP (1) EP3921030B1 (https=)
JP (2) JP7451543B2 (https=)
KR (1) KR102924196B1 (https=)
CN (1) CN113692304B (https=)
AU (1) AU2020218180B2 (https=)
BR (1) BR112021015544A2 (https=)
DK (1) DK3921030T3 (https=)
ES (1) ES2968807T3 (https=)
FI (1) FI3921030T3 (https=)
HR (1) HRP20240012T1 (https=)
HU (1) HUE064734T2 (https=)
IL (1) IL285113B2 (https=)
LT (1) LT3921030T (https=)
MX (1) MX2021009396A (https=)
PL (1) PL3921030T3 (https=)
PT (1) PT3921030T (https=)
RS (1) RS65040B1 (https=)
SA (1) SA521422733B1 (https=)
SG (1) SG11202108599SA (https=)
SI (1) SI3921030T1 (https=)
SM (1) SMT202400003T1 (https=)
WO (1) WO2020163268A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240012T1 (hr) * 2019-02-06 2024-03-29 Eli Lilly And Company Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori
AU2021295422A1 (en) 2020-06-25 2023-02-23 Idorsia Pharmaceuticals Ltd Cyclobutyl-urea derivatives
TW202330471A (zh) * 2021-09-30 2023-08-01 日商住友製藥股份有限公司 環丙醯胺衍生物
EP4433472A1 (en) 2021-11-19 2024-09-25 Icagen, LLC Pyridine compounds as kv7.2 enhancers
JP2024542881A (ja) * 2021-11-19 2024-11-18 アイカジェン・エルエルシー Kv7.2阻害剤としての新規ヘテロアリール-尿素化合物
EP4452944A1 (en) 2021-12-22 2024-10-30 Icagen, LLC Cyclopropyl compounds
JP2025506201A (ja) 2022-02-15 2025-03-07 アイカジェン・エルエルシー 新規なビシクロペンタン誘導体
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3
IT202200024963A1 (it) 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257481A (zh) * 1997-03-25 2000-06-21 英国阿斯特拉药品有限公司 新的吡啶衍生物及其含有它们的药用组合物
CN100345823C (zh) * 2003-01-14 2007-10-31 赛特凯恩蒂克公司 化合物、组合物及方法
AU2005233642A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyridines as potassium ion channel modulators
CN1993347A (zh) * 2004-07-29 2007-07-04 默克公司 钾通道抑制剂
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물
CA2828456C (en) * 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
CN103709097A (zh) * 2012-09-28 2014-04-09 中国科学院上海药物研究所 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
JP6364472B2 (ja) * 2013-03-15 2018-07-25 デシフェラ ファーマシューティカルズ,エルエルシー 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体
CA2936886A1 (en) * 2014-02-27 2015-08-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof
TWI664166B (zh) 2014-10-24 2019-07-01 日商小野藥品工業股份有限公司 Kcnq2至5通道活化劑
JP6943239B2 (ja) * 2016-04-22 2021-09-29 小野薬品工業株式会社 Kcnq2〜5チャネル活性化剤
HRP20240012T1 (hr) * 2019-02-06 2024-03-29 Eli Lilly And Company Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori

Also Published As

Publication number Publication date
JP2024063191A (ja) 2024-05-10
SMT202400003T1 (it) 2024-03-13
AU2020218180B2 (en) 2025-09-04
HRP20240012T1 (hr) 2024-03-29
ES2968807T3 (es) 2024-05-14
BR112021015544A2 (pt) 2021-10-26
PT3921030T (pt) 2024-01-12
KR102924196B1 (ko) 2026-02-06
IL285113A (en) 2021-09-30
US11840516B2 (en) 2023-12-12
CN113692304B (zh) 2025-03-18
US11208383B2 (en) 2021-12-28
JP2022519744A (ja) 2022-03-24
US20220073464A1 (en) 2022-03-10
IL285113B2 (en) 2025-10-01
WO2020163268A1 (en) 2020-08-13
CA3128975A1 (en) 2020-08-13
FI3921030T3 (fi) 2024-01-08
DK3921030T3 (da) 2024-01-02
US12344584B2 (en) 2025-07-01
US20200247752A1 (en) 2020-08-06
US20240076269A1 (en) 2024-03-07
US20250282725A1 (en) 2025-09-11
JP7451543B2 (ja) 2024-03-18
HUE064734T2 (hu) 2024-04-28
IL285113B1 (en) 2025-06-01
AU2020218180A1 (en) 2021-08-19
SA521422733B1 (ar) 2024-02-08
SG11202108599SA (en) 2021-09-29
EP3921030B1 (en) 2023-10-11
SI3921030T1 (sl) 2024-03-29
MX2021009396A (es) 2021-09-10
PL3921030T3 (pl) 2024-05-06
EP3921030A1 (en) 2021-12-15
RS65040B1 (sr) 2024-02-29
CN113692304A (zh) 2021-11-23
KR20210126040A (ko) 2021-10-19

Similar Documents

Publication Publication Date Title
LT3921030T (lt) 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai
SMT202400470T1 (it) 4-(4-(4-(((2-(2,6-diossopiperidin-3-il)-l-ossoisoindolin-4-il)ossi)metil)benzil)piperazin-l-il)-3-fluorobenzonitrile come composto antiproliferativo
PH12018500264A1 (en) 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
EP3919055A4 (en) HETEROCYCLIC COMPOUND
EP4066893A4 (en) HETEROCYCLIC COMPOUND
DK1599450T3 (da) Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister
LT4084779T (lt) 1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos
IL280598A (en) 2,6-diamino pyridine compounds
EP3578555A4 (en) DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASEACTIVITY
IL282006B1 (en) Treatment of bone tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
EP3553057A4 (en) (HETERO) ARYLAMIDE COMPOUND TO INHIBIT PROTEIN KINASE ACTIVITY
PL3827004T3 (pl) Pochodne 4-(1,3,4-oksadiazol-2-ilo)pirydyn-2(1h)-onu jako inhibitory deacetylazy histonowej 6 (hdac6) do leczenia np. zakażeń
EP3946288A4 (en) SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES USED AS SELECTIVE CDK12/13 INHIBITORS
EP3927696C0 (en) CRYSTAL FORM OF 1-(1-OXO-1,2-DIHYDROISOQUINOLEIN-5-YL)-5-(TRIFLUOROMETHYL)-(2-(TRIFLUOROMETHYL)PYRIDIN-4-YL)-1H-PYRAZOLE-4-CARBOXAMIDE MONOHYDRATE
DK3947711T3 (da) Urinstofbiosensorer, der er stabiliseret ved rumtemperatur
DK3227273T3 (da) Sammensætninger, som omfatter 2-((1-(2(4-fluorphenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-on, til behanlding af skizofreni
MX2016005324A (es) Composiciones pesticidas y metodos relacionados.
MX390378B (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
DK3421475T3 (da) Kondenseret heterocyklisk forbindelse med bundne heterocyklusser og salte deraf, landbrugs-/havebrugsinsekticid indeholdende nævnte forbindelse og fremgangsmåde til anvendelse af nævnte insekticid
IL260403B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
EP3774768A4 (en) Substituted pyrazole derivatives as selective cdk12/13 inhibitors
DK3559010T3 (da) Fremgangsmåde til fremstilling af 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedion og salte deraf
EP4051021C0 (en) TOBACCO-CONTAINING AEROSOL-GENERATING COMPOSITION COMPRISING MEDIUM-CHAIN TRIGLYCERIDES
EP3553056A4 (en) (HETERO) ARYLAMIDE COMPOUND TO INHIBIT PROTEIN KINASE ACTIVITY
HRP20251602T1 (hr) Vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu